XBiotech Inc. (XBIT)
NASDAQ: XBIT · Real-Time Price · USD
2.890
-0.070 (-2.36%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Company Description
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases.
The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases.
It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and general inflammation.
The company was incorporated in 2005 and is headquartered in Austin, Texas.
XBiotech Inc.
Country | United States |
Founded | 2005 |
IPO Date | Apr 15, 2015 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 92 |
CEO | John Simard |
Contact Details
Address: 5217 Winnebago Lane Austin, Texas 78744 United States | |
Phone | 512 386 2900 |
Website | xbiotech.com |
Stock Details
Ticker Symbol | XBIT |
Exchange | NASDAQ |
Stock Type | Common Stock |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001626878 |
CUSIP Number | 98400H102 |
ISIN Number | CA98400H1029 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
John Simard | Founder, President, Chief Executive Officer and Chairman |
Angela Hu | Director of Finance |
Dr. Sushma Shivaswamy Ph.D. | Chief Scientific Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Apr 7, 2025 | 8-K | Current Report |
Apr 1, 2025 | 8-K | Current Report |
Mar 18, 2025 | 10-K | Annual Report |
Jan 27, 2025 | SCHEDULE 13G/A | Filing |
Jan 27, 2025 | SCHEDULE 13G/A | Filing |
Dec 31, 2024 | 8-K | Current Report |
Nov 13, 2024 | 10-Q | Quarterly Report |
Aug 12, 2024 | 10-Q | Quarterly Report |
Jun 20, 2024 | 8-K | Current Report |
May 10, 2024 | 10-Q | Quarterly Report |